echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Go one step further!

    Go one step further!

    • Last Update: 2021-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Go one step further! Scientists propose a new treatment plan for esophageal cancer
    Go one step further! Scientists propose a new treatment plan for esophageal cancer to go further! Scientists propose a new treatment plan for esophageal cancer

    Recently, the research team of Professor Adam Bass of Harvard Medical School’s Dana-Farber Cancer Institute published a paper in the academic journal Enterology (GUT), revealing the combination of CDK4/6 inhibitors and pan ERBB family inhibitors can effectively inhibit the growth of esophageal squamous cell carcinoma.


    Esophageal cancer is a common gastrointestinal tumor.


    With the support of the "Cancer Genome Atlas Project (TCGA)", the Adam Bass team has been committed to the search, confirmation and treatment of new targets for esophageal cancer.


    In the past few years, they have further carried out a number of experiments around the treatment plan of CDK4/6.


    "Although'palbociclib' can significantly slow down the growth of tumors compared to the control group, the tumors continue to grow.


    Next, they confirmed from data analysis that the growth of most squamous cancer cells is also dependent on epidermal growth factor protein (ERBBs).


    Squamous cancer cell lines are more dependent on the epidermal growth factor family (ERBBs) (photo courtesy of the research team)

    Squamous cancer cell lines are more dependent on the epidermal growth factor family (ERBBs) (photo courtesy of the research team)

    Therefore, the researchers combined the two drugs, the CDK4/6 inhibitor "palbociclib" and the pan-ERBBs inhibitor "afatinib".


    In addition, they also explained the reasons why the combination therapy is effective.


    The researchers hope that the application of this new combination drug strategy can be promoted as soon as possible, and it will provide new options for the clinical treatment of esophageal squamous cell cancer and benefit patients as soon as possible.


    The first authors of this article are Dr.


    Related paper information: org/10.


    org/10.
    1136/gutjnl-2020-323276" target="_blank">https://doi.
    org/10.
    1136/gutjnl-2020-323276
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.